公开(公告)号：US11304960B2

公开(公告)日：2022-04-19

申请号：US12350930

申请日：2009-01-08

Applicant: Chandrashekar Giliyar ,  Nachiappan Chidambaram ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

Inventor： Chandrashekar Giliyar ,  Nachiappan Chidambaram ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

IPC: A61K31/569 ,  A61K9/48 ,  A61K31/568 ,  A61K9/00 ,  A61K47/10 ,  A61K47/14 ,  A61K47/44

Abstract: Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.

公开(公告)号：US20150038475A1

公开(公告)日：2015-02-05

申请号：US14500438

申请日：2014-09-29

Applicant: Basawaraj Chickmath ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Mahesh Patel ,  Srinivasan Venkateshwaran

Inventor： Basawaraj Chickmath ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Mahesh Patel ,  Srinivasan Venkateshwaran

IPC: A61K9/20 ,  A61K47/10 ,  A61K47/36 ,  A61K31/568

CPC classification number: A61K9/2031 ,  A61K9/14 ,  A61K9/146 ,  A61K9/148 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/1694 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/282 ,  A61K9/2853 ,  A61K9/286 ,  A61K9/2866 ,  A61K9/4866 ,  A61K9/4875 ,  A61K31/568 ,  A61K47/10 ,  A61K47/36 ,  A61K47/38 ,  A61K47/40

Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37° C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier.

Abstract translation: 本公开涉及含有十一酸睾酮的药物组合物和口服剂型，以及相关的治疗方法。 在一个实施方案中，口服剂型可以包括治疗有效量的十一酸睾酮和药学上可接受的载体。 可以配制剂型，使得当使用USP II型装置在1000mL的8重量％Triton X-100在水中在37℃和100rpm下测量时，口服剂型释放至少20％以上的睾酮 十一酸十一酸酯比不含药学上可接受的载体的含有口服剂型的等效剂量十一酸睾酮。

公开(公告)号：US20150018324A1

公开(公告)日：2015-01-15

申请号：US14500498

申请日：2014-09-29

Applicant: Basawaraj Chickmath ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

Inventor： Basawaraj Chickmath ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

IPC: A61K9/28 ,  A61K47/38 ,  A61K47/10 ,  A61K9/20 ,  A61K31/568 ,  A61K47/36

CPC classification number: A61K9/2031 ,  A61K9/14 ,  A61K9/146 ,  A61K9/148 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/1694 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/282 ,  A61K9/2853 ,  A61K9/286 ,  A61K9/2866 ,  A61K9/4866 ,  A61K9/4875 ,  A61K31/568 ,  A61K47/10 ,  A61K47/36 ,  A61K47/38 ,  A61K47/40

Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37° C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier.

公开(公告)号：US20120322780A1

公开(公告)日：2012-12-20

申请号：US13592258

申请日：2012-08-22

Applicant: Chandrashekar Giliyar ,  Nachiappan Chidambaram ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

Inventor： Chandrashekar Giliyar ,  Nachiappan Chidambaram ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

IPC: A61K31/568 ,  A61P5/26

CPC classification number: A61K31/569 ,  A61K9/0053 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/4875 ,  A61K31/568 ,  A61K47/10 ,  A61K47/14 ,  A61K47/44

Abstract: Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.

Abstract translation: 本文提供了适用于向个体提供治疗有效量的至少一种类固醇的含甾族化合物的组合物。 本文还提供包含适于在一段时间内提供治疗有效和安全量的睾酮的睾酮和/或睾酮衍生物的组合物。 还提供了通过给予本文所述的个体组合物来治疗个体中的和/或睾酮缺乏症的方法。

公开(公告)号：US06727401B1

公开(公告)日：2004-04-27

申请号：US09022504

申请日：1998-02-12

Applicant: Srinivasan Venkateshwaran ,  Danyi Quan

Inventor： Srinivasan Venkateshwaran ,  Danyi Quan

IPC: A61F1300

CPC classification number: A61K9/7061 ,  A61F13/105 ,  A61K8/4946 ,  A61Q3/00

Abstract: A device for treating antifungal infections of toenails and fingernails is made up of an occlusive backing layer and a pressure sensitive adhesive matrix layer in which is uniformly dispersed an effective amount of an antifungal agent and, optionally, a chemical enhancer. The matrix layer has a first surface adhering to the backing layer and a second surface adapted to be in diffusional contact with the infected nail and surrounding skin area. The device is configured, when applied, to cover and adhere to the nail and surrounding skin areas for an extended period of time without causing irritation to the skin or inhibiting normal physical activity while providing a continuous delivery of antifungal agent to the infected area.

Abstract translation: 用于治疗脚趾甲和指甲的真菌感染的装置由闭塞背衬层和压敏粘合剂基质层组成，其中均匀分散有效量的抗真菌剂和任选的化学增强剂。 基质层具有粘附到背衬层的第一表面和适于与受感染的指甲和周围皮肤区域扩散接触的第二表面。 该装置在施用时被配置为在延长的时间段内覆盖并粘附到指甲和周围皮肤区域，而不会对皮肤产生刺激或抑制正常的身体活动，同时提供抗真菌剂到感染区域的连续递送。

公开(公告)号：US5780050A

公开(公告)日：1998-07-14

申请号：US504430

申请日：1995-07-20

Applicant: Uday Jain ,  Srinivasan Venkateshwaran ,  Charles D. Ebert

Inventor： Uday Jain ,  Srinivasan Venkateshwaran ,  Charles D. Ebert

IPC: A61K9/70 ,  A61K31/565 ,  A61K31/57 ,  A61K47/04 ,  A61K47/10 ,  A61K47/14 ,  A61K47/16 ,  A61K47/20 ,  A61K47/30 ,  A61K47/32 ,  A61K47/44 ,  A61P5/24 ,  A61P5/38 ,  A61F13/00

CPC classification number: A61K9/7061 ,  A61K31/568 ,  A61K31/569 ,  A61K31/57 ,  A61K31/573 ,  A61K31/575

Abstract: A stabilized patch device for transdermal drug delivery of steroid drugs containing a 3-keto-4-en functional group is described, wherein the patch comprises an effective amount of the steroid drug and a carrier that is free of acid functional groups. The device can further contain additives such as a penetration enhancer or excipient, so long as such additives are also free of acid functional groups. The device can be either a matrix patch or a liquid reservoir patch. In a matrix patch, the carrier is a biocompatible polymeric adhesive with which the steroid drug is intimately admixed. The adhesive is preferably an acrylic polymer or copolymer. In a liquid reservoir patch, the carrier is a controlled-viscosity composition containing a thinner or thickener. Preferred steroid drugs include certain corticosteroids and sex hormones, such as progestins and androgens. A method of stabilizing such steroid drugs during storage in transdermal patches is also disclosed.

Abstract translation: 描述了一种用于经皮药物递送含有3-酮-4-烯官能团的类固醇药物的稳定补片装置，其中补片包含有效量的类固醇药物和不含酸官能团的载体。 该装置可以进一步含有添加剂如渗透促进剂或赋形剂，只要这些添加剂也不含酸官能团。 该装置可以是矩阵补丁或液体储存器补丁。 在基质贴剂中，载体是与类固醇药物紧密混合的生物相容的聚合物粘合剂。 粘合剂优选为丙烯酸类聚合物或共聚物。 在液体储存贴片中，载体是含有较薄或增稠剂的受控粘度组合物。 优选的类固醇药物包括某些皮质类固醇和性激素，如孕激素和雄激素。 还公开了在透皮贴剂储存期间稳定这种类固醇药物的方法。

公开(公告)号：US09107921B2

公开(公告)日：2015-08-18

申请号：US14555043

申请日：2014-11-26

Applicant: Chandrashekar Giliyar ,  Satish Kumar Nachaegari ,  Chidambaram Machiappan ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

Inventor： Chandrashekar Giliyar ,  Satish Kumar Nachaegari ,  Chidambaram Machiappan ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

IPC: A61K31/485 ,  A61K31/194 ,  A61K31/4402 ,  A61K45/06 ,  A61K31/09 ,  A61K31/137 ,  A61K9/20

CPC classification number: A61K31/485 ,  A61K9/0053 ,  A61K9/2054 ,  A61K31/09 ,  A61K31/137 ,  A61K31/194 ,  A61K31/4402 ,  A61K45/06 ,  A61K2300/00

Abstract: A pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The tablet is a matrix tablet and a single-dose administration of one or more tablets to a subject under fasted conditions provides a mean Cm˜ for each of the first active agent and the second active agent that is 70% to 135% of a respective mean Cm˜ provided by administering an immediate release oral dosage form to a subject under fasted conditions every 4 to 6 hours over a 12 hour time period, wherein cumulative dosage amounts administered over the 12 hour time period of each active agent is equivalent to the respective amount of each active agent in the pharmaceutical tablet.

Abstract translation: 提供每12小时一次口服给药的药片。 片剂包括第一活性剂，其为三氧基活性剂，第二活性剂和释放速率控制非离子含氧基的亲水性聚合物。 片剂是基质片剂，并且在禁食条件下向受试者单剂量施用一种或多种片剂，为每种第一活性剂和第二活性剂提供平均Cm〜，其为相应的70％至135％ 平均Cm〜通过在禁食条件下每隔4至6小时在12小时时间内向受试者施用立即释放的口服剂型，其中在每个活性剂的12小时时间段内施用的累积剂量相当于相应的 药物片剂中每种活性剂的量。

公开(公告)号：US20150165049A1

公开(公告)日：2015-06-18

申请号：US14633545

申请日：2015-02-27

Applicant: Chandrashekar Giliyar ,  Srinivasan Venkateshwaran ,  Basawaraj Chickmath ,  Satish Kumar Nachaegari ,  Chidambaram Nachiappan ,  Mahesh Patel

Inventor： Chandrashekar Giliyar ,  Srinivasan Venkateshwaran ,  Basawaraj Chickmath ,  Satish Kumar Nachaegari ,  Chidambaram Nachiappan ,  Mahesh Patel

IPC: A61K47/44 ,  A61K9/14 ,  A61K47/14 ,  A61K47/10 ,  A61K47/20 ,  A61K47/32 ,  A61K9/20 ,  A61K47/12 ,  A61K47/22 ,  A61K31/57 ,  A61K47/26

CPC classification number: A61K31/57 ,  A61K8/63 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/145 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/4841 ,  A61K9/4858 ,  A61K9/4866 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K47/32 ,  A61K47/44 ,  A61K2800/10 ,  A61Q11/00

Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.

Abstract translation: 本发明提供含有17-羟孕酮酯的生物可利用的口服剂型以及相关方法。 口服剂型可以配制用于妊娠支持，并且可以包括治疗有效量的17-羟孕酮和药学上可接受的载体的酯。 在另一个实施方案中，提供了用于妊娠支持的药学上可接受的口服剂型。 药学上可接受的口服剂量可以包括治疗有效量的17-羟孕酮和可药用载体的酯。 口服剂型可以使用USP Type-II溶出装置在90mL的90RPM的90mL去离子水和0.5（w / v）十二烷基硫酸钠的条件下，在37℃下以50RPM释放至少20wt％ 60分钟后17-羟孕酮酯的剂量，或在替代释放中60分钟后至少20重量％比不含载体的等效给药口服剂型更多。

公开(公告)号：US20070281927A1

公开(公告)日：2007-12-06

申请号：US11448597

申请日：2006-06-06

Applicant: Shanthakumar Tyavanagimatt ,  David Fikstad ,  Chandrashekar Giliyar ,  Mahesh Patel ,  Srinivasan Venkateshwaran

Inventor： Shanthakumar Tyavanagimatt ,  David Fikstad ,  Chandrashekar Giliyar ,  Mahesh Patel ,  Srinivasan Venkateshwaran

IPC: A61K31/5415

CPC classification number: A61K31/5415 ,  A61K9/2054 ,  A61K9/4858 ,  A61K9/5084

Abstract: Methods and compositions for delivering a meloxicam compound are disclosed and described. In one aspect, a method may include perorally administering to a subject a therapeutically effective amount of a meloxicam compound that provides a meloxicam plasma concentration within 1 hour which is at least about 40% of the maximum plasma concentration attained by the formulation. In another aspect, a composition may include a therapeutically effective amount of a meloxicam compound in a pharmaceutically acceptable carrier including at least one of an alkalizer or a solubilizer, with the meloxicam compound having a solubility in the carrier that is greater than about 1.0 mg/gm.

Abstract translation: 公开和描述了递送美洛昔康化合物的方法和组合物。 一方面，方法可以包括向受试者口服施用治疗有效量的美洛昔康化合物，所述美洛昔康化合物在1小时内提供美洛昔康血浆浓度，其为制剂达到的最大血浆浓度的至少约40％。 另一方面，组合物可以包括药学上可接受的载体中的治疗有效量的美洛昔康化合物，其包括碱化剂或增溶剂中的至少一种，其中美洛昔康化合物在载体中的溶解度大于约1.0mg / gm。

公开(公告)号：US20050096365A1

公开(公告)日：2005-05-05

申请号：US10700838

申请日：2003-11-03

Applicant: David Fikstad ,  Srinivasan Venkateshwaran ,  Chandrashekar Giliyar ,  Feng-Jing Chen ,  Mahesh Patel

Inventor： David Fikstad ,  Srinivasan Venkateshwaran ,  Chandrashekar Giliyar ,  Feng-Jing Chen ,  Mahesh Patel

IPC: A61K9/20 ,  A61K9/48 ,  A61K31/17 ,  A61K31/265 ,  A61K31/28 ,  A61K31/34 ,  A61K31/35 ,  A61K31/66 ,  A61K47/14 ,  A61K47/22 ,  A61K47/34 ,  A61K47/40 ,  A61K31/724 ,  A61K31/355 ,  A61K31/426

CPC classification number: A61K31/66 ,  A61K9/2013 ,  A61K9/2031 ,  A61K9/205 ,  A61K9/4808 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/17 ,  A61K31/265 ,  A61K31/28 ,  A61K31/34 ,  A61K31/35 ,  A61K47/14 ,  A61K47/22 ,  A61K47/34 ,  A61K47/40

Abstract: Pharmaceutical compositions with synchronized solubilizer release as well as various methods associated therewith, are disclosed and described. More specifically, the aqueous solubility of a drug is enhanced by synchronized release of a solubilizer.